RARE
$41.91
Ultragenyx Pharmaceu
$1.89
4.72%
RARE
Earnings Whisper ®
N/A
4th Quarter December 2024
Consensus:  ($1.28)
Revenue:  $146.71 Mil
Thursday
Feb 13
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Tuesday, November 5, 2024

What do you expect when RARE reports earnings?
Beat
Meet
Miss

Where is RARE's stock price going from here?
Up
Flat
Down
Stock chart of RARE
Analysts
Summary of analysts' recommendations for RARE
Score
Grade
Pivots
Resistance
$47.83
$46.17
$43.10

$41.44

Support
$38.37
$36.71
$33.64
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalARRAY TechnologiesRegeneron PharmaceuticalsMerck & Co.Bristol Myers SquibbEli LillyPfizerJohnson & JohnsonInsmed
›